title: Long-term effects of pharmacological therapy for vasovagal syncope on the basis of reproducibility during head-up tilt testing.
abstract: The purpose of this study was to determine the efficacy of long-term pharmacological therapy selected on the basis of a head-up tilt test (HUT) in patients in whom reproducibility of the HUT response was demonstrable in the initial study. The HUT (80 degrees upright) was performed for 15 min with or without an infusion of isoproterenol (0.01-0.03 microgram/kg per min) in 54 patients with recurrent unexplained syncope. When vasovagal syncope was induced (positive response), the HUT was repeated to examine the test reproducibility. Vasovagal syncope was induced in 24 patients during HUT alone, and in 30 patients during the HUT with isoproterenol. Acute reproducibility was observed in 49/54 (91%) patients. In the tilt-positive patients, HUT was repeated after an intravenous administration of propranolol (0.1 mg/kg) or disopyramide (1 mg/kg) (acute test). Propranolol proved effective in 21 (80%) of 26 patients, and disopyramide in 13 (56%) of 23 patients. Thereafter, evaluation was done on the long-term clinical follow-up of the pharmacological intervention selected on the basis of the acute test in the 34 patients in whom the HUT could not induce vasovagal syncope after the oral administration of the pharmacological agent (propranolol 60 mg/day, disopyramide 300 mg/day). Thirty-two of 34 patients (94%) did not develop syncopal attacks during a 44 +/- 12-month period. Thus, in patients with unexplained syncope, HUT appears to have a high degree of acute reproducibility, and the acute drug response guided by HUT may be used to develop an effective long-term pharmacological therapy.
authors.affiliation: Third Department of Internal Medicine, Showa University School of Medicine, Tokyo, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Nakagawa
authors.forename: Y
authors.initials: Y
authors.lastname: Kobayashi
authors.forename: S
authors.initials: S
authors.lastname: Kikushima
authors.forename: M
authors.initials: M
authors.lastname: Shinohara
authors.forename: C
authors.initials: C
authors.lastname: Obara
authors.forename: Y
authors.initials: Y
authors.lastname: Zinbo
authors.forename: K
authors.initials: K
authors.lastname: Chiyoda
authors.forename: A
authors.initials: A
authors.lastname: Miyata
authors.forename: K
authors.initials: K
authors.lastname: Tanno
authors.forename: T
authors.initials: T
authors.lastname: Baba
authors.forename: T
authors.initials: T
authors.lastname: Katagiri
mesh_terms: D000284:Administration, Oral; D000328:Adult; D004206:Disopyramide / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D018475:Head-Down Tilt; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D011433:Propranolol / Q000008:administration & dosage*; D013565:Sympatholytics / Q000008:administration & dosage*; D019462:Syncope, Vasovagal / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome
chemical_list: D013565:Sympatholytics; D011433:Propranolol; D004206:Disopyramide